2-Hour Cancer Blood Test to Transform Tumor Detection
Posted on 17 Sep 2025
Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies, often delay detection and limit how frequently patients can be monitored. Now, a new blood-based test aims to detect cancer signals more quickly, cheaply, and accurately, potentially transforming how recurrence and treatment response are tracked.
OncoRevive (Victoria, Australia) has developed a reagent kit that mixes with a patient’s blood sample to detect tumor signals like circulating DNA and proteins. The technology, aided by artificial intelligence (AI) analysis, delivers results in under two hours and reduces costs by about 40% compared with current liquid biopsy methods. Unlike solid biopsies, which require invasive sampling, this test is painless and avoids reliance on advanced clinical expertise.
OncoRevive has already tested 100 patient samples in the United States and is collaborating with universities to access biobanks for further validation. The company’s findings show that the test can detect cancer from a single circulating tumor cell, while existing assays typically require multiple cells for a positive result. This improved sensitivity and accessibility suggest it may outperform current methods of monitoring disease recurrence.
OncoRevive’s initial focus is breast cancer, with plans to expand to colon cancer and other tumor types. The company is preparing two products: a research-use-only kit for universities and clinics, and a diagnostic kit aimed at clinical use. To gain regulatory approval from the US Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), OncoRevive plans to expand testing to 700 patient samples, with the research kit expected to launch next year and full approval targeted by 2028.
Related Links:
OncoRevive
